PMID- 35126103
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220208
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and 
      Meta-Analysis.
PG  - 752440
LID - 10.3389/fphar.2021.752440 [doi]
LID - 752440
AB  - Objective: To evaluate the efficacy and safety of ertugliflozin in patients with 
      type 2 diabetes. Methods: MEDLINE, EMBASE, and Cochrane Library were searched 
      (July 31, 2021) for phase II/III randomized clinical trials, which reported the 
      efficacy and safety of ertugliflozin. Continuous variables were calculated as 
      weighted mean difference (WMD) and associated 95% confidence intervals (CIs); 
      dichotomous data were expressed as risk ratios (RRs) with 95% CIs. Results: Nine 
      randomized clinical trials including 5638 type 2 diabetes patients were included. 
      For efficacy, ertugliflozin significantly reduced HbA1c (%) (WMD -0.452%; 95% CI 
      -0.774 to -0.129), fasting plasma glucose (FPG) (WMD -0.870 mmol/L; 95% CI -1.418 
      to -0.322), body weight (WMD -1.774 kg; 95% CI -2.601 to -0.946), and blood 
      pressure levels (systolic blood pressure: WMD -2.572 mmHg; 95% CI -3.573 to 
      -1.571 and diastolic blood pressure: WMD -1.152 mmHg; 95% CI -2.002 to -0.303) 
      compared with placebo and other hypoglycaemic agents. Compared with placebo, 
      ertugliflozin was superior in reducing HbA1c (%) (WMD -0.641%) and FPG (WMD 
      -1.249 mmol/L). And compared with active agents, ertugliflozin also could 
      decrease HbA1c by 0.215% and FPG by 0.266 mmol/L. The interactive effect between 
      different controls was significant (P (interaction) of 0.039). For safety, 
      similar to other sodium-glucose cotransporter type-2 inhibitors, ertugliflozin 
      mainly increased the risk of genital mycotic infection (RR: 4.004; 95% CI 
      2.504-6.402). There was no significant difference in the incidence of any adverse 
      events (AEs), AEs related to study drug, serious AEs, deaths, and 
      discontinuations due to AEs. Results were consistent with the most primary 
      outcomes in subgroups analysis and sensitivity analysis. Conclusion: 
      Ertugliflozin was relatively effective and tolerated in patients with type 2 
      diabetes compared with placebo or other hypoglycaemic agents, except for a high 
      risk of genital mycotic infection. Systematic Review Registration: 
      (ClinicalTrials.gov), identifier (CRD42020206356).
CI  - Copyright (c) 2022 Liu, Shi, Xu, Wu, Gu and Lin.
FAU - Liu, Li
AU  - Liu L
AD  - Department of Pharmacy, Ren Ji Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Shi, Fang-Hong
AU  - Shi FH
AD  - Department of Pharmacy, Ren Ji Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Xu, Hua
AU  - Xu H
AD  - Department of Endocrinology, Ren Ji Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Wu, Yue
AU  - Wu Y
AD  - Department of Pharmacy, Renmin Hospital, Wuhan University, Wuhan, China.
FAU - Gu, Zhi-Chun
AU  - Gu ZC
AD  - Department of Pharmacy, Ren Ji Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Lin, Hou-Wen
AU  - Lin HW
AD  - Department of Pharmacy, Ren Ji Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - School of Medicine, Tongji University, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220120
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8811446
OTO - NOTNLM
OT  - adverse drug event
OT  - ertugliflozin
OT  - glycaemia
OT  - meta-analysis
OT  - sodium-glucose cotransporter type-2 inhibitor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/08 06:00
MHDA- 2022/02/08 06:01
PMCR- 2022/01/20
CRDT- 2022/02/07 05:29
PHST- 2021/08/03 00:00 [received]
PHST- 2021/12/21 00:00 [accepted]
PHST- 2022/02/07 05:29 [entrez]
PHST- 2022/02/08 06:00 [pubmed]
PHST- 2022/02/08 06:01 [medline]
PHST- 2022/01/20 00:00 [pmc-release]
AID - 752440 [pii]
AID - 10.3389/fphar.2021.752440 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Jan 20;12:752440. doi: 10.3389/fphar.2021.752440. 
      eCollection 2021.